AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2871286 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral flow ratios greater than 2
Number of subjects: 20
Study 30594482 — intervention group
Group type: EXPERIMENTAL
Intervention: Follitropin delta
Number of subjects: 701
Study 30594482 — intervention group
Group type: COMPARATOR
Intervention: Follitropin alfa
Number of subjects: 701
Study 27588932 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 units of oxytocin diluted in 500 mL of lactated Ringer solution
Number of subjects: 189
Study 27588932 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 units of oxytocin diluted in 500 mL of lactated Ringer solution
Number of subjects: 189
Study 27588932 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 units of oxytocin diluted in 500 mL of lactated Ringer solution
Number of subjects: 189
Study 26061985 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoridated varnish (Clinpro)
Number of subjects: 50
Study 26061985 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etch primer system (Transbond Plus Self‐Etch Primer)
Number of subjects: 50
Study 26061985 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin infiltrate (ICON)
Number of subjects: 50
Study 26061985 — intervention group
Group type: COMPARATOR
Intervention: Intact enamel
Number of subjects: 50
Study 26061985 — intervention group
Group type: COMPARATOR
Intervention: Demineralized enamel
Number of subjects: 50
Study 23117015 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate treadmill training (repetitive intervals to moderate claudication pain)
Number of subjects: 60
Study 23117015 — intervention group
Group type: COMPARATOR
Intervention: Pain-free treadmill training (repetitive intervals to onset of claudication pain)
Number of subjects: 60
Study 21586693 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 401
Study 21586693 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent
Number of subjects: 401
Study 21586693 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with early ST
Number of subjects: 401
Study 21586693 — intervention group
Group type: COMPARATOR
Intervention: Patients without early ST
Number of subjects: 401
Study 19796737 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg clopidogrel loading dose
Number of subjects: 3602
Study 19796737 — intervention group
Group type: COMPARATOR
Intervention: bivalirudin
Number of subjects: 3602
Study 16426270 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP rs1043994
Number of subjects: 97
Study 16426270 — intervention group
Group type: COMPARATOR
Intervention: NOTCH3 gene mutations in exons 3 and 4
Number of subjects: 97
Study 15451899 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal insulin (1.6 mg)
Number of subjects: 38
Study 15451899 — intervention group
Group type: COMPARATOR
Intervention: Carrier solution (control)
Number of subjects: 38
Study 11253562 — intervention group
Group type: EXPERIMENTAL
Intervention: Budipine (3 x 20 mg/d)
Number of subjects: 53
Study 11253562 — intervention group
Group type: COMPARATOR
Intervention: Amantadine (3 x 100 mg/d)
Number of subjects: 53
Study 9306302 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic community (TC)
Number of subjects: 0
Study 9306302 — intervention group
Group type: EXPERIMENTAL
Intervention: Community residence (CR)
Number of subjects: 0
Study 8173712 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy (intravenous tissue plasminogen activator in 561 patients, urokinase in 102 patients, combination of tissue plasminogen activator and urokinase in 147 patients)
Number of subjects: 810
Study 2946815 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) plus doxorubicin plus mitomycin C (FAM)
Number of subjects: 133
Study 2946815 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptozotocin plus mitomycin C plus 5-FU (original SMF)
Number of subjects: 133
Study 2946815 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptozotocin plus mitomycin C plus 5-FU with 5-FU and streptozotocin administered in five-day courses
Number of subjects: 133
Study 31365489 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringer's acetate solution infusion
Number of subjects: 20
Study 31365489 — intervention group
Group type: COMPARATOR
Intervention: Infusions in normovolemic state
Number of subjects: 20
Study 29226545 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide/oxygen mixture
Number of subjects: 240
Study 29226545 — intervention group
Group type: COMPARATOR
Intervention: Oxygen (control)
Number of subjects: 240
Study 27923439 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated readings (RR)
Number of subjects: 168
Study 27923439 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide reading (WR)
Number of subjects: 168
Study 27923439 — intervention group
Group type: COMPARATOR
Intervention: Business as usual
Number of subjects: 168
Study 25019535 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist orienting the patient toward affect
Number of subjects: 50
Study 25019535 — intervention group
Group type: EXPERIMENTAL
Intervention: Sense of self
Number of subjects: 50
Study 25019535 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist intervention
Number of subjects: 50
Study 22161726 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral weight loss intervention
Number of subjects: 338
Study 22161726 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased physical activity
Number of subjects: 338
Study 22161726 — intervention group
Group type: COMPARATOR
Intervention: Reduction in UI frequency
Number of subjects: 338
Study 19996309 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal insulin administration
Number of subjects: 9
Study 19996309 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 9
Study 18221410 — intervention group
Group type: EXPERIMENTAL
Intervention: lumiracoxib 400 mg o.d.
Number of subjects: 18325
Study 18221410 — intervention group
Group type: COMPARATOR
Intervention: naproxen 500 mg b.d.
Number of subjects: 18325
Study 18221410 — intervention group
Group type: COMPARATOR
Intervention: ibuprofen 800 mg t.d.s.
Number of subjects: 18325
Study 16838125 — intervention group
Group type: EXPERIMENTAL
Intervention: IVGTT
Number of subjects: 40
Study 12615747 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 1290000
Study 12615747 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors (general)
Number of subjects: 1290000
Study 10850829 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with spinal cord injury (SCI)
Number of subjects: 364
Study 10850829 — intervention group
Group type: COMPARATOR
Intervention: Control population (ambulatory adults)
Number of subjects: 364
Study 9190631 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysis fluid containing acetate
Number of subjects: 0
Study 9190631 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysis fluid containing bicarbonate
Number of subjects: 0
Study 9190631 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 8249554 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA)
Number of subjects: 31
Study 8249554 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular (im) morphine
Number of subjects: 31
Study 3902378 — intervention group
Group type: EXPERIMENTAL
Intervention: Equine antisera (anti-diencephalon and anti-stomach tissue)
Number of subjects: 40
Study 3902378 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 40
Study 29237235 — intervention group
Group type: EXPERIMENTAL
Intervention: everolimus + reduced tacrolimus (EVR+rTAC)
Number of subjects: 284
Study 29237235 — intervention group
Group type: COMPARATOR
Intervention: standard tacrolimus (TAC Control)
Number of subjects: 284
Study 26693858 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg/kg body mass)
Number of subjects: 14
Study 26693858 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 mg/kg)
Number of subjects: 14
Study 24955739 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral valproic acid (VPA) 500mg once daily for 1 year
Number of subjects: 30
Study 24955739 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 30
Study 22549680 — intervention group
Group type: EXPERIMENTAL
Intervention: Frankel's functional regulator 1b
Number of subjects: 83
Study 22549680 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 83
Study 20395080 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance Training (BT)
Number of subjects: 60
Study 20395080 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 60
Study 18554232 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonexclusive control questions
Number of subjects: 120
Study 18554232 — intervention group
Group type: COMPARATOR
Intervention: Exclusive control questions
Number of subjects: 120
Study 15914346 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants of diabetic mothers (IDMs)
Number of subjects: 83
Study 15914346 — intervention group
Group type: COMPARATOR
Intervention: Macrosomic infants of nondiabetic mothers
Number of subjects: 83
Study 15914346 — intervention group
Group type: COMPARATOR
Intervention: Infants of pregestational diabetic mothers
Number of subjects: 83
Study 12695832 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast injection at 0.1 ml/kg body weight s(‐1) over 21 s without flush (Group 1)
Number of subjects: 180
Study 12695832 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast injection at 0.1 ml/kg body weight s(‐1) over 21 s with a 30-ml flush (Group 2)
Number of subjects: 180
Study 12695832 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast injection at 0.07 ml/kg body weight s(‐1) over 30 s without flush (Group 3)
Number of subjects: 180
Study 12695832 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast injection at 0.07 ml/kg body weight s(‐1) over 30 s with a 30-ml flush (Group 4)
Number of subjects: 180
Study 12695832 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of a flush
Number of subjects: 180
Study 12695832 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher injection rate protocols (Groups 1 and 2)
Number of subjects: 180
Study 10328403 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated perimetry and daytime IOP curve taken every second month during the 2-year follow-up
Number of subjects: 82
Study 7813100 — intervention group
Group type: EXPERIMENTAL
Intervention: Alphaglobin
Number of subjects: 21
Study 7813100 — intervention group
Group type: COMPARATOR
Intervention: Sandoglobulin/Gamimune
Number of subjects: 21
Study 1661447 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Heparin (SH)
Number of subjects: 0
Study 1661447 — intervention group
Group type: COMPARATOR
Intervention: Low Molecular Weight Heparin (LMWH)
Number of subjects: 0
Study 6760376 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic cholangiography
Number of subjects: 52
Study 6760376 — intervention group
Group type: COMPARATOR
Intervention: Transhepatic cholangiography
Number of subjects: 52
Study 31761447 — intervention group
Group type: EXPERIMENTAL
Intervention: Active iTBS
Number of subjects: 26
Study 31761447 — intervention group
Group type: COMPARATOR
Intervention: Sham iTBS
Number of subjects: 26
Study 30012389 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (n=47)
Number of subjects: 96
Study 30012389 — intervention group
Group type: COMPARATOR
Intervention: Mock laser control (n=49)
Number of subjects: 96
Study 27358159 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular injection of hyaluronic acid (HA)
Number of subjects: 70
Study 27358159 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular injection of oxygen ozone (O2O3)
Number of subjects: 70
Study 27358159 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of hyaluronic acid (HA) and oxygen ozone (O2O3)
Number of subjects: 70
Study 24776953 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative monotherapy with a second AED (Group A)
Number of subjects: 264
Study 24776953 — intervention group
Group type: COMPARATOR
Intervention: Add-on treatment with a second AED (Group B)
Number of subjects: 264
Study 24776953 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life based on the Quality Of Life In Epilepsy scale
Number of subjects: 264
Study 24776953 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolerability
Number of subjects: 264
Study 22570370 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence and Intensification of Medications intervention
Number of subjects: 4099
Study 22570370 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 4099
Study 19493565 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine
Number of subjects: 1911
Study 19493565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1911
Study 17456583 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir 75 mg
Number of subjects: 28
Study 17456583 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir 150 mg
Number of subjects: 28
Study 17456583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 17456583 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir (all doses)
Number of subjects: 28
Study 15156331 — intervention group
Group type: EXPERIMENTAL
Intervention: Potentially unstable fixation group (n=15)
Number of subjects: 40
Study 15156331 — intervention group
Group type: COMPARATOR
Intervention: Stable fixation group (n=25)
Number of subjects: 40
Study 12487226 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (5 mg for ages 6 to < 14 years; 10 mg for > 14 years)
Number of subjects: 16
Study 12487226 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 12487226 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 16
Study 9660559 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic k-space filling with bolus chase 3D MRDSA using a 25-ml gadolinium dose and a multiple-phase 3D fast gradient-echo sequence.
Number of subjects: 7
Study 9660559 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex subtraction technique for image acquisition.
Number of subjects: 7
Study 7665422 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% O2
Number of subjects: 16
Study 2539648 — intervention group
Group type: EXPERIMENTAL
Intervention: IE (ifosfamide, 1.5 g/m2, days 1 through 5; etoposide, 120 mg/m2, days 3 through 5)
Number of subjects: 718
Study 2539648 — intervention group
Group type: COMPARATOR
Intervention: CAV (cyclophosphamide, 600 mg/m2, days 1 and 2; doxorubicin, 50 mg/m2, day 1; vincristine, 2 mg, day 1)
Number of subjects: 718
Study 2539648 — intervention group
Group type: COMPARATOR
Intervention: PE (cisplatin, 90 mg/m2, day 1; etoposide, 150 mg/m2, days 3 through 5)
Number of subjects: 718
Study 2539648 — intervention group
Group type: EXPERIMENTAL
Intervention: IAV (ifosfamide, 2 g/m2, days 1 to 5; doxorubicin, 25 mg/m2, days 1 and 2; vincristine, 2 mg, day 1)
Number of subjects: 718
Study 2539648 — intervention group
Group type: COMPARATOR
Intervention: PE or JE (carboplatin, 300 mg/m2, day 1; etoposide, 120 mg/m2, days 1 to 3)
Number of subjects: 718
Study 362519 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dose of 1 g twice daily for one day
Number of subjects: 22
Study 362519 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 50 mg/kg
Number of subjects: 22
Study 362519 — intervention group
Group type: COMPARATOR
Intervention: Higher dosage regime (1 g twice daily)
Number of subjects: 22
Study 30825563 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy
Number of subjects: 26
Study 30825563 — intervention group
Group type: COMPARATOR
Intervention: Traditional debridement therapy
Number of subjects: 26
Study 28093383 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised minimal acupuncture at LI4
Number of subjects: 147
Study 28093383 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-standardised individual acupuncture inspired by Traditional Chinese Medicine
Number of subjects: 147
Study 28093383 — intervention group
Group type: COMPARATOR
Intervention: No acupuncture (control group)
Number of subjects: 147
Study 26376691 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 0
Study 26376691 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 0
Study 26376691 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam
Number of subjects: 0
Study 26376691 — intervention group
Group type: COMPARATOR
Intervention: Active placebo
Number of subjects: 0
Study 23572225 — intervention group
Group type: EXPERIMENTAL
Intervention: LATG with DST
Number of subjects: 52
Study 23572225 — intervention group
Group type: EXPERIMENTAL
Intervention: 21-mm EEA stapler
Number of subjects: 52
Study 23572225 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-mm EEA stapler
Number of subjects: 52
Study 23572225 — intervention group
Group type: COMPARATOR
Intervention: Open total gastrectomy
Number of subjects: 52
Study 21376474 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress condition
Number of subjects: 0
Study 21376474 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 19671476 — intervention group
Group type: EXPERIMENTAL
Intervention: PR‐Porcelain Repair Kit (Bisco) [etching with 9.5% hydrofluoric acid+silanization+adhesive]
Number of subjects: 30
Study 19671476 — intervention group
Group type: EXPERIMENTAL
Intervention: CJ‐CoJet Repair Kit (3M ESPE) [(chairside silica coating with 30microm SiO(2)+silanization (ESPE)‐Sil)+adhesive (Visio‐Bond)]
Number of subjects: 30
Study 19671476 — intervention group
Group type: EXPERIMENTAL
Intervention: CL‐Clearfil Repair Kit [diamond surface roughening, etching with 40% H(3)PO(4)+Clearfil Porcelain Bond Activator+Clearfil SE Bond]
Number of subjects: 30
Study 17904297 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5mg testosterone
Number of subjects: 20
Study 17904297 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15203264 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation group (beta-radiation with a (188)Re-filled balloon catheter system)
Number of subjects: 20
Study 15203264 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-stented adjacent segments)
Number of subjects: 20
Study 11181985 — intervention group
Group type: EXPERIMENTAL
Intervention: Active NCPAP therapy
Number of subjects: 0
Study 11181985 — intervention group
Group type: COMPARATOR
Intervention: Sub-therapeutic NCPAP therapy
Number of subjects: 0
Study 9554631 — intervention group
Group type: EXPERIMENTAL
Intervention: RESPIMAT device delivering fenoterol
Number of subjects: 0
Study 9554631 — intervention group
Group type: COMPARATOR
Intervention: MDI alone delivering fenoterol
Number of subjects: 0
Study 9554631 — intervention group
Group type: COMPARATOR
Intervention: MDI with Aerochamber delivering fenoterol
Number of subjects: 0
Study 9554631 — intervention group
Group type: EXPERIMENTAL
Intervention: RESPIMAT device delivering flunisolide
Number of subjects: 0
Study 9554631 — intervention group
Group type: COMPARATOR
Intervention: MDI plus spacer delivering flunisolide
Number of subjects: 0
Study 9554631 — intervention group
Group type: EXPERIMENTAL
Intervention: RESPIMAT device with baffle delivering flunisolide
Number of subjects: 0
Study 7851269 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic subjects (mean glomerular filtration rate 216 ml/min)
Number of subjects: 15
Study 7851269 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic subjects (corrected for body size, mean glomerular filtration rate 165.6 ml/min per 1.73 m2)
Number of subjects: 15
Study 7851269 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic subjects
Number of subjects: 15
Study 7851269 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic subjects (albumin excretion median 61 mg/day)
Number of subjects: 15
Study 3072940 — intervention group
Group type: EXPERIMENTAL
Intervention: HR-6 solutions containing adenosine triphosphate (0.5 or 5 mg/ml)
Number of subjects: 11
Study 3072940 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 29505742 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate rotator cuff repair (Group 1, n = 44)
Number of subjects: 78
Study 29505742 — intervention group
Group type: COMPARATOR
Intervention: Delayed rotator cuff repair after 6 months of nonoperative treatment (Group 2, n = 34)
Number of subjects: 78
Study 27640126 — intervention group
Group type: EXPERIMENTAL
Intervention: Insert (two-page evidence-based article)
Number of subjects: 23508
Study 27640126 — intervention group
Group type: EXPERIMENTAL
Intervention: Outsert (short, directive message)
Number of subjects: 23508
Study 27640126 — intervention group
Group type: EXPERIMENTAL
Intervention: Insert + Outsert
Number of subjects: 23508
Study 27640126 — intervention group
Group type: COMPARATOR
Intervention: Control (no educational messages)
Number of subjects: 23508
Study 24072718 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal continuity of care (COC) with the same PCP
Number of subjects: 4393
Study 24072718 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Modified Modified Continuity Index (MMCI)
Number of subjects: 4393
Study 24072718 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbreviated duration of PCP care (< 1 year)
Number of subjects: 4393
Study 22087736 — intervention group
Group type: EXPERIMENTAL
Intervention: Jebsen‐Taylor hand function test (JHFT)
Number of subjects: 90
Study 22087736 — intervention group
Group type: EXPERIMENTAL
Intervention: Motoric performance test (MLS)
Number of subjects: 90
Study 22087736 — intervention group
Group type: EXPERIMENTAL
Intervention: Number connection test
Number of subjects: 90
Study 22087736 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient self-assessment
Number of subjects: 90
Study 22087736 — intervention group
Group type: COMPARATOR
Intervention: Control group (D)
Number of subjects: 90
Study 20736152 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir (800/100 mg once daily) alone (DRVrMono)
Number of subjects: 256
Study 20736152 — intervention group
Group type: COMPARATOR
Intervention: Darunavir/ritonavir with nucleoside analogues (DRVrNRTI)
Number of subjects: 256
Study 20736152 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir (DRVrMono)
Number of subjects: 256
Study 18511605 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (10 mg once daily)
Number of subjects: 251
Study 18511605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251